#METABOLOMICS WORKBENCH Toadpup1956_20210209_120248 DATATRACK_ID:2464 STUDY_ID:ST001690 ANALYSIS_ID:AN002760 PROJECT_ID:PR001086
VERSION             	1
CREATED_ON             	February 11, 2021, 1:00 pm
#PROJECT
PR:PROJECT_TITLE                 	Parallel multi-omics in high-risk subjects for the identification of integrated
PR:PROJECT_TITLE                 	biomarker signatures of type 1 diabetes
PR:PROJECT_TYPE                  	Untargeted metabolomics: MS qualitative analysis
PR:PROJECT_SUMMARY               	MS qualitative analysis of human blood samples to identify early-identification
PR:PROJECT_SUMMARY               	biomarkers for type 1 diabetes
PR:INSTITUTE                     	Duke University
PR:DEPARTMENT                    	Duke Molecular Physiology Institute, School of Medicine
PR:LABORATORY                    	Metabolomics
PR:LAST_NAME                     	Bain
PR:FIRST_NAME                    	James
PR:ADDRESS                       	300 N Duke Street, Durham, NC, 27701, USA
PR:EMAIL                         	james.bain@duke.edu
PR:PHONE                         	919 479 2320
PR:FUNDING_SOURCE                	NIH, NIDDK
PR:PROJECT_COMMENTS              	This data represents the untargeted metabolomic analysis of the samples
PR:CONTRIBUTORS                  	O. Alcazar, L.F. Hernandez, E.S. Nakayasu, C. Ansong, C.D. Nicora, C. Ansong,
PR:CONTRIBUTORS                  	M.J. Muehlbauer, J.R. Bain, C.J. Myer, S.J. Bhattacharya, P. Buchwald, and M.H.
PR:CONTRIBUTORS                  	Abdulreda
#STUDY
ST:STUDY_TITLE                   	Untargeted metabolomic analysis of human blood samples via qualitative GC-MS for
ST:STUDY_TITLE                   	T1D biomarker identification
ST:STUDY_TYPE                    	Qualitative GC-MS biomarker identification
ST:STUDY_SUMMARY                 	"Blood from human subjects at high risk for T1D (and healthy controls; n=4 each)
ST:STUDY_SUMMARY                 	were subjected to parallel unlabeled proteomics, metabolomics, lipidomics, and
ST:STUDY_SUMMARY                 	transcriptomics. The integrated dataset was analyzed using Ingenuity Pathway
ST:STUDY_SUMMARY                 	Analysis (IPA) software for disturbances in the at-risk subjects compared to the
ST:STUDY_SUMMARY                 	controls. The final quadra-omics dataset contained 2292 proteins, 328 miRNAs, 75
ST:STUDY_SUMMARY                 	metabolites, and 41 lipids that were detected in all samples. Disease/function
ST:STUDY_SUMMARY                 	enrichment analyses consistently indicated increased activation, proliferation,
ST:STUDY_SUMMARY                 	and migration of immune cells, particularly, CD4 T-lymphocytes and macrophages.
ST:STUDY_SUMMARY                 	Integrated molecular network predictions highlighted central involvement and
ST:STUDY_SUMMARY                 	activation of NF-κB, TGF-β, VEGF, arachidonic acid, and arginase, and
ST:STUDY_SUMMARY                 	inhibition of miRNA Let-7a-5p. Parallel multi-omics provided a comprehensive
ST:STUDY_SUMMARY                 	picture of disturbances in high-risk T1D subjects and helped identify an
ST:STUDY_SUMMARY                 	associated integrated biomarker signature, which could ultimately facilitate the
ST:STUDY_SUMMARY                 	classification of T1D progressors from non-progressors."
ST:INSTITUTE                     	Duke University
ST:DEPARTMENT                    	Duke Molecular Physiology Institute, School of Medicine
ST:LABORATORY                    	Metabolomics
ST:LAST_NAME                     	Bain
ST:FIRST_NAME                    	James
ST:ADDRESS                       	300 N Duke St, Durham, NC, 27701, USA
ST:EMAIL                         	james.bain@duke.edu
ST:PHONE                         	919 479 2320
ST:TOTAL_SUBJECTS                	9
#SUBJECT
SU:SUBJECT_TYPE                  	Human
SU:SUBJECT_SPECIES               	Homo sapiens
SU:TAXONOMY_ID                   	9606
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	140365	1	Condition:High-risk T1D	RAW_FILE_NAME=Miami-01
SUBJECT_SAMPLE_FACTORS           	2019 0605 TL	2	Condition:Healthy control	RAW_FILE_NAME=Miami-02
SUBJECT_SAMPLE_FACTORS           	467191	3	Condition:New-onset (post-prandial)	RAW_FILE_NAME=Miami-03
SUBJECT_SAMPLE_FACTORS           	467191 small	4	Condition:New-onset (fasting)	RAW_FILE_NAME=Miami-04
SUBJECT_SAMPLE_FACTORS           	145569	5	Condition:High-risk T1D	RAW_FILE_NAME=Miami-05
SUBJECT_SAMPLE_FACTORS           	2019 0605 BH	6	Condition:Healthy control	RAW_FILE_NAME=Miami-06
SUBJECT_SAMPLE_FACTORS           	2019 0605 YM	7	Condition:Healthy control	RAW_FILE_NAME=Miami-07
SUBJECT_SAMPLE_FACTORS           	245361	8	Condition:High-risk T1D	RAW_FILE_NAME=Miami-08
SUBJECT_SAMPLE_FACTORS           	2019 0605 MG	9	Condition:Healthy control	RAW_FILE_NAME=Miami-09
SUBJECT_SAMPLE_FACTORS           	Blank	Ghost (blank)	Condition:Process blank	RAW_FILE_NAME=Ghost
SUBJECT_SAMPLE_FACTORS           	-	RT	Condition:-	RAW_FILE_NAME=-
#COLLECTION
CO:COLLECTION_SUMMARY            	"Blood samples (~20 mL/subject in EDTA) were collected from consented
CO:COLLECTION_SUMMARY            	male/female subjects considered at high risk for T1D during routine visits as
CO:COLLECTION_SUMMARY            	part of the ongoing TrialNet’s Natural History Study of the Development of
CO:COLLECTION_SUMMARY            	Type 1 Diabetes (Pathway to Prevention Study) TN-01 study (n=4)."
CO:SAMPLE_TYPE                   	Blood (plasma)
#TREATMENT
TR:TREATMENT_SUMMARY             	"Subjects in the TN-01 study are tested semi-annually for the appearance of new
TR:TREATMENT_SUMMARY             	or additional autoantibodies and are evaluated metabolically by oral glucose
TR:TREATMENT_SUMMARY             	tolerance test (OGTT) to assess their progression toward clinical diagnosis of
TR:TREATMENT_SUMMARY             	T1D. Samples from healthy subjects (n=4) were collected as part of another study
TR:TREATMENT_SUMMARY             	approved by the IRB of the University of Miami (study number 11995-115). These
TR:TREATMENT_SUMMARY             	trials are conducted in accordance with the principles of the Declaration of
TR:TREATMENT_SUMMARY             	Helsinki and consistent with the Good Clinical Practice guidelines of the
TR:TREATMENT_SUMMARY             	International Conference on Harmonization. The protocol for the ancillary study,
TR:TREATMENT_SUMMARY             	under which the current multi-omics analyses were performed, was approved by
TR:TREATMENT_SUMMARY             	TrialNet (study ID number 195) and its IRB. The four high-risk subjects in the
TR:TREATMENT_SUMMARY             	present report were staged for their risk level according to the TrialNet
TR:TREATMENT_SUMMARY             	staging/scoring system, which considers family history, genetic susceptibility
TR:TREATMENT_SUMMARY             	according to haplotype (e.g., HLA-DQ/DR), the number of autoantibodies, and OGTT
TR:TREATMENT_SUMMARY             	results as follows: low-risk (1 autoantibody and normal OGTT); moderate-risk
TR:TREATMENT_SUMMARY             	(2–3 autoantibodies and normal OGTT); high-risk (4–5 autoantibodies and
TR:TREATMENT_SUMMARY             	normal OGTT); and very high-risk (4–5 autoantibodies and abnormal OGTT)."
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	See uploaded protocol
SP:SAMPLEPREP_PROTOCOL_FILENAME  	Toadpup1956_20210209_120248_PR_SP_PlasmaPrep_non-targeted_MBX.pdf
SP:SAMPLEPREP_PROTOCOL_COMMENTS  	Please treat these as confidential disclosures of in-house sample prep.
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_TYPE           	GC
CH:INSTRUMENT_NAME               	Agilent 6890N
CH:COLUMN_NAME                   	Agilent DB5-MS (30m x 0.25mm, 0.25um)
CH:METHODS_FILENAME              	Toadpup1956_20210209_120248_PR_MS_Data_acquisition_protocol.pdf
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
AN:ANALYSIS_PROTOCOL_FILE        	Toadpup1956_20210209_120248_PR_MS_Data_acquisition_protocol.pdf
#MS
MS:INSTRUMENT_NAME               	Agilent 5975B
MS:INSTRUMENT_TYPE               	Single quadrupole
MS:MS_TYPE                       	EI
MS:ION_MODE                      	POSITIVE
MS:MS_COMMENTS                   	Acquired using Agilent MassHunter Acquisition software. Feature assignment
MS:MS_COMMENTS                   	completed using AMDIS Analysis.
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	minutes
MS_METABOLITE_DATA_START
Samples	1	2	3	4	5	6	7	8	9	Ghost (blank)
Factors	Condition:High-risk T1D	Condition:Healthy control	Condition:New-onset (post-prandial)	Condition:New-onset (fasting)	Condition:High-risk T1D	Condition:Healthy control	Condition:Healthy control	Condition:High-risk T1D	Condition:Healthy control	Condition:Process blank
Pyruvic acid	19.27	19.15	19.59	18.76	19.9	16.12	17.73	19.6	19.84	
Lactic acid	24.4	24.13	24.25	24.19	25.32	24.29	23.6	24.49	24.82	12.83
2-Hydroxyisobutyric acid	13.26	13.58				12.91				
Glycolic acid		16.69	15.34	16.95	17.57	17.16	15.46		16.65	
3-Methyl pyruvic acid			13		11.28					
Alanine	20.26	21.12	20.13	20.85	20.9	20.9	21.04	20.41	20.73	
2-Ketovaline	15.6	14.05	15.48	15.65	15.46	14.26	14.84	14.33	14.76	
2-Hydroxybutyric acid	17.6	18.17	18.92	18.3	19.33	19.08	18.57	18.49	19.33	
P-Cresol				13.56	11.85	13.46	12.12	13.36	12.07	
Leucine	17.29	17.49	17.49	17.6	17.93	17.52	18.07	17.53	16.85	
3-Hydroxybutyric acid	18.74	19.55	19.25	18.93	20.34	21.96	18.92	19.94	17.72	
2-Hydroxyvaleric acid	14.66	16.87	14.72	16.52	16.32	15.29	15.13	14.08	15.14	
N-Methylalanine/2-Aminobutanoic acid	14.62	16.1	15.09	15.35	16.45	16.02	15.76	17.48	15.21	
2-Ketoleucine/ketoisoleucine	17.22	15.55	16.87	17.03	16.97	16.78	16.22	17.02	16.96	
Valine	18.53	20.28	18.78	20.15	20.39	19.47	19.59	19.83	18.98	
Urea	25.05	26.03	25.25	26.2	26.22	25.5	25.6	25.73	25.4	
Caprylic acid	15.42	16.97	13	15.75	15.4	15.18	16.63	16.9	14.43	
Ethanolamine	14.17	13.67	14.8	15.09	15.06	15.5	16.63	17.59	14.8	
Phosphoric acid	23.93	24.92	24.59	25.03	25.41	25.29	24.29	24.65	25.07	20.07
Glycerol	21.39	20.95	23.12		23.4	23.36	24.29	23.97	21.25	18.21
Isoleucine/Leucine	16.83	18.11	17.45	17.86	19.46	18.28	16.91	16.75	16.41	
Proline	18.54	19.97	17.49	18.55	20.2	19.24	17.65	17.16	16.62	
Glycine	18.96	18.69	19.63	19.34	20.44	20.85	19.88	20.88	20.06	
Succinic acid				16.79	16.78	19.06		16.46		
Maleic acid	15	15.77			16	15.8	13.3		15.97	
Glyceric acid	15.72	17.13	16.36	17.89	17.09	18.28	17.08	17.32	17.57	
Uracil						12.91		11.32		
Fumaric acid				11.93	13.24	11.79			12.62	
Serine	17.69	19.91	18.1	19.02	20.44	20.48	15.95	17.47	18.43	
Pelargonic acid	11.28	13.06			12.32	13.77	12.2		13.22	
Threonine	18.95	21.51	18.89	20.06	21.44	20.69	17.36	18.03	19.26	
beta-Alanine		10.99			11.93		12.57	12.74	11.17	
Capric acid	14.59	11.4	12.52	12.96	13.39	14.32	15.65	15.05		
Aminomalonic acid	17.73	19.9		19.68	20.65	20.57	17.64		20.12	
Malic acid	13.36	15.54		16.58	16.87	17.74	14.3	15.66	15.57	
Threitol/Erythritol	16.11	17.92	16.24	16.98	17.39	16.81	15.71	16.49	16.69	
Aspartic acid	13.3	15.96	13.56	15.24	16.14	15.35	13.01	13.78	14.41	
3-Methyloxyindole		15.85			17.4					
Methionine	15.81	17.41	15.46	16.73	17.85	17.05	13.66	15.84	16.04	
Hydroxyprolines	16.04	16.57	16.28	16.49	19.59	16.29	13.77	15.74	16.84	
Erythronic acid	14.11	16.01	14.95	16.35	16.56	16.68	15	15.66	16.23	
Threonic acid	17.36	18.43	17.88	18.98		19.03	17.48	17.78	18.46	
Oxoglutaric acid	15.79			17.65	18.43	17			13.88	
Glutamic acid	19.33	18.53	17.58	20.63	21.72	22.02	17.96	18.45	19.52	
3-Hydroxymethylglutaricacid				19.04		19.69				
Phenylalanine	18.83	20.28	19.28	20.19	20.8	20.26	19.12	19.46	19.23	
Lauric acid	15.65	13.94	16.6	14.72	16.19	17.14	16.29	17.45		
Aldopentoses	12.92	14.46	13.41	12.77	12.15	14.67	14.89	14.96	13.87	
Pyrophosphate	14.72	16.08	16.78	16.81	16.93	17.58	16.83	16.89	17.92	
Asparagine	16.65	18.21	17.45	17.68	18.8	18.57	16.53	17.33	17.59	
Pentitols	14.74	17.11	15.01	16.19	16.33	15.69	15.06	15.58	15.46	
6-Deoxyhexose	13.78	12.78	13.13	12.54	14.44	12.79	13.69	14.08		
sn-Glycero-3-phosphate	11.94	16.47		16.89	16.56	17.71	13.41	14.84	15.35	
Gentisic acid			12.03			13.17				
Pentonic acids		13.17		13.75		11.59	13.74	14.04	11.7	
Glutamine	19.7	21.55	20.56	21.88	21.94	21.39	19.52	20.49	21.49	
Phosphoethanolamine						12.9	15.11	14.77		
3-Phosphoglyceric acid			16.23		16.99			14.79		
Shikimic acid	15.75	16.27	16.23	15.48	17.21	16.57	14.38		17.76	
Hippuric acid						13.01			14.43	
3-Methylhistidine				11.81	13.32					
Hypoxanthine	14.14	15.5	13.48		10.42	14.37	15.11	14.48	15.37	
Citric acid/isocitric acid	19.59	21.26	20.5	21.05	22.38	22	19.63	20.99	21.15	
Ornithine	18.4	18.81	18.47	18.62	19.9	19.3	19.63	19.18	18.77	
Arginine/Citrulline					12.4	12.93			12.1	
1,5-Anhydrosorbitol	22.01	21.46	21.09	22.36	22.51	22.43	21.13	22.22	21.44	
Myristic acid	17.29	15.51	19.02	15.87	16.78	16.95	17.2	19.72	14.45	12.14
Quinic acid		13.13		14.17	13.67	15.36	15.59			
Caffeine		16.51		13.54		14.84	17.48			
Fructose or similar ketohexose	16.85	19.68	16.23	19	18.92	17.32	17.82	17.82	17.86	
Dehydroascorbic acid		19.93		18.85	19.77	19.88	17.05	17.69	20.24	
Hexose	26.45	26.76	26.49	26.71	26.74	26.63	26.56	26.57	26.99	10.45
Histidine	15.88	18.29	16.14	17.94	18.22	18.14	15.16	16.16	17.31	
Lysine	18.59	20.68	19.89	20.16	21.03	20.8	19.72	20.02	20.47	
Methyl palmitate	16.79	21.56	16.61	19.95	18.57	20.99	21.23	21.56	18.92	
Tyrosine	19.2	20.38	19.79	19.82	20.4	20.46	19.9	20.1	19.82	
Gluconic acid	18.73	19.89	19.06	19.9	20.05	20.14	19.36	19.28	21.34	
Indoleacetic acid	12.82		12.78	13.23	12.66	14.29	13.6	12.82	12.31	
3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acid		12.9	13.21			12.37	12.5		13.73	
5-Hydroxylysine			12.16		13.14	12.39	10.08		12.83	
Palmitoleic acid	17.11	17.27	19.49	17.58	19.14	19.21	17.61	20.37	16.66	
Palmitic acid	23.14	22.49	23.8	22.68	23.06	23.4	23.09	23.64	22.15	21.9
3-Indolepropionic acid	11.18		14.93	11.67	12.88	14.8	13.66	13.72	14.97	
Myo-inositol	18.75	20.17	19.08	20.14	19.84	20.05	18.88	19.49	19.83	
Uric acid	21.2	19.97	20.81	21.26	21.41	21.81	19.52	19.42	21.17	
Methyl linoleate		18.78		17.57	15.42	19.41	19.58	20.59	16.27	
Methyl oleate		18.22		16.56	14.23	18.02	18.37	19.14	15.47	
Methyl stearate	16.57	21.52	17.98	20.46	18.72	21.84	22.02	22.58	19.53	
Heptadecanoic acid/Octadecanol	13.95	12.15	14.85	13.18	13.94	14.34	14.34	15.83		10.45
3-Indolelactic acid	12.84			14.03						
1-Methyltryptophan	11.85	14.44	14.26	15.72	15.77		10.55	12.52		
Linoleic acid	21.79	19.53	23.05	21.15	21.53	22.52	21.8	22.78	20.46	17.04
Tryptophan	18.83	17.92	18.77	19.8	20.79	19.47	18.93	19.27	20.03	
Oleic acid	22.89	20.87	23.97	21.57	22.77	23.14	23.03	23.74	20.6	14.81
Cystine	14.84	16.79	14.14	15.13	17.43	15.95			16.36	
Hexose 6-phosphate		10.84		10.7		12.97		10.76		
Arachidonic acid	16.26	17.53	17.91	18.78	17.61	19.14	18.2	18.21	18.34	16.18
Arachidic acid/ 1-Heneicosanol	12.4		13.99	13.97	13.65	13.24	13.63	13.79	11.87	
5-Methoxytryptamine/Serotonin						16.89	16.66	17.07		
MG 0:0/16:0/0:0	17.14	17.8	18.26	18.04	18.02	17.93	17.93	17.8	18.04	15
Docosahexaenoic acid			14.36	14.48	12.27	15.77	15.31	14.28	14.26	
Cellobiose or similar disaccharide	16.26	18.86	14.97	17.75	17.57	19.8	19.19	16.9	18.05	
MG 0:0/18:0/0:0	20.52	21.08	21.55	21.22	21.04	21.08	21.15	20.95	21.17	18.44
MG 18:1(9Z)/0:0/0:0	12.24	13.06	13.54	13.02	14.07	14.07	13.6	15.34	13.87	12.38
Maltose or similar disaccharide	12.46	16.64	11.93	15.22	14.67	17.79	17.06	13.67	15.6	
gamma-Tocopherol	15.03	16.35	16.77	15.35	15.43	16.06	15.51	15.74	16.79	
AMP		12.58			10.36					
alpha-Tocopherol	17.85	19.6	19.24	19.65	18.84	19.65	19.62	19.76	19.35	
Cholesterol	24.06	25.82	25.32	25.25	24.86	25.67	25.75	25.68	25.22	
Campesterol			11.63		13.16	13.07		16.7	12.74	
Sitosterol					12.89	13.88		15.81		
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	Retention time
Pyruvic acid	6.599
Lactic acid	6.753
2-Hydroxyisobutyric acid	6.813
Glycolic acid	7.005
3-Methyl pyruvic acid	7.384
Alanine	7.403
2-Ketovaline	7.49
2-Hydroxybutyric acid	7.749
P-Cresol	8.203
Leucine	8.233
3-Hydroxybutyric acid	8.258
2-Hydroxyvaleric acid	8.307
N-Methylalanine/2-Aminobutanoic acid	8.438
2-Ketoleucine/ketoisoleucine	9.032
Valine	9.073
Urea	9.526
Caprylic acid	9.808
Ethanolamine	9.816
Phosphoric acid	9.877
Glycerol	9.885
Isoleucine/Leucine	10.18
Proline	10.264
Glycine	10.374
Succinic acid	10.478
Maleic acid	10.551
Glyceric acid	10.663
Uracil	10.798
Fumaric acid	10.977
Serine	11.079
Pelargonic acid	11.145
Threonine	11.419
beta-Alanine	12.012
Capric acid	12.419
Aminomalonic acid	12.532
Malic acid	12.744
Threitol/Erythritol	12.971
Aspartic acid	13.154
3-Methyloxyindole	13.16
Methionine	13.168
Hydroxyprolines	13.236
Erythronic acid	13.408
Threonic acid	13.607
Oxoglutaric acid	13.83
Glutamic acid	14.362
3-Hydroxymethylglutaricacid	14.362
Phenylalanine	14.479
Lauric acid	14.79
Aldopentoses	14.806
Pyrophosphate	14.801
Asparagine	14.932
Pentitols	15.471
6-Deoxyhexose	15.547
sn-Glycero-3-phosphate	15.932
Gentisic acid	15.945
Pentonic acids	15.953
Glutamine	16.104
Phosphoethanolamine	16.191
3-Phosphoglyceric acid	16.416
Shikimic acid	16.417
Hippuric acid	16.457
3-Methylhistidine	16.467
Hypoxanthine	16.482
Citric acid/isocitric acid	16.569
Ornithine	16.575
Arginine/Citrulline	16.655
1,5-Anhydrosorbitol	16.931
Myristic acid	16.948
Quinic acid	16.975
Caffeine	17.026
Fructose or similar ketohexose	17.178
Dehydroascorbic acid	17.189
Hexose	17.359
Histidine	17.642
Lysine	17.671
Methyl palmitate	17.769
Tyrosine	17.845
Gluconic acid	17.985
Indoleacetic acid	18.106
3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acid	18.239
5-Hydroxylysine	18.531
Palmitoleic acid	18.727
Palmitic acid	18.923
3-Indolepropionic acid	19.277
Myo-inositol	19.297
Uric acid	19.363
Methyl linoleate	19.414
Methyl oleate	19.473
Methyl stearate	19.706
Heptadecanoic acid/Octadecanol	19.847
3-Indolelactic acid	20.084
1-Methyltryptophan	20.095
Linoleic acid	20.457
Tryptophan	20.465
Oleic acid	20.508
Cystine	21.133
Hexose 6-phosphate	21.303
Arachidonic acid	21.817
Arachidic acid/ 1-Heneicosanol	22.408
5-Methoxytryptamine/Serotonin	22.539
MG 0:0/16:0/0:0	23.267
Docosahexaenoic acid	23.343
Cellobiose or similar disaccharide	24.624
MG 0:0/18:0/0:0	24.711
MG 18:1(9Z)/0:0/0:0	24.798
Maltose or similar disaccharide	24.825
gamma-Tocopherol	26.521
AMP	26.889
alpha-Tocopherol	27.466
Cholesterol	27.612
Campesterol	28.313
Sitosterol	28.945
METABOLITES_END
#END